Why Gleevec-Type Drugs Control, But Do Not Eradicate Leukemia

Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family. The research was presented Monday, Dec. 8, at the 50th Annual American Society of Hematology conference in San Francisco.

More: continued here

Filed under: Lymphoma / Leukemia on December 11th, 2008